 Pfizer Inc. PFE, -0.08 said Wednesday that the Food and Drug Administration and the European Medicines Agency accepted the new drug application for its ulcerative colitis treatment candidate. The FDA is expected to make a decision whether to approve etrasimod in the second half of next year. 